011040 — Kyungdong Pharm Income Statement
0.000.00%
- KR₩187bn
- KR₩203bn
- KR₩163bn
- 57
- 59
- 75
- 75
Annual income statement for Kyungdong Pharm, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 176,500 | 173,828 | 177,611 | 182,718 | 162,674 |
Cost of Revenue | |||||
Gross Profit | 103,569 | 98,608 | 97,170 | 94,994 | 88,306 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 139,194 | 154,877 | 161,855 | 174,906 | 187,347 |
Operating Profit | 37,306 | 18,950 | 15,755 | 7,812 | -24,673 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 34,944 | 19,339 | 18,432 | 17,941 | -18,503 |
Provision for Income Taxes | |||||
Net Income After Taxes | 22,831 | 12,873 | 12,627 | 12,113 | -20,730 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 20,126 | 12,459 | 12,672 | 12,161 | -20,708 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 20,126 | 12,459 | 12,672 | 12,161 | -20,708 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 498 | 507 | 459 | 463 | -771 |
Dividends per Share |